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mation were calculated. RESULTS: Taking into account the results from MC simu-
lations, the PTA/S alternative is the most expensive and less effective (€ 24,581 and
6.857 QALYs), but attending to small differences and the large variability on results
between alternatives, these results are not conclusive. The least costly alternative
is PTA/S/BP (€ 18,351), with an effectiveness of 7.049 QALYs. PTA/S/BP shows higher
effectiveness than PTA/S, but lower effectiveness than BP (7.281 QALYs). The cost of
the BP alternative is € 24,056. PTA/S/BP and BP alternatives show higher probabili-
ties of being efficient alternatives. If the willingness to pay is € 30,000/QALY, op-
portunity cost of implementing PTA/S/BP would exceed € 15,000 per patient
treated. CONCLUSIONS: Although the results of effectiveness identified PTA/S/BP
as the most efficient alternative for a willingness to pay less than € 40,000/QALY,
the probability of making a proper decision is only about 50%. This situation, to-
gether with the high opportunity costs, encourages the development of new clin-
ical trials or observational studies in our environment in order to remove uncer-
tainty over the results.
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OBJECTIVES: Ranolazine is an antianginal agent that was approved for use in the
EU in 2008 as an add-on therapy for the symptomatic treatment of chronic angina
pectoris in patients who are inadequately controlled by or intolerant to first-line
antianginal therapies, such as beta blockers and calcium antagonists. The objective
of this study is to assess the cost utility of ranolazine relative to placebo as an
add-on therapy for the symptomatic treatment of patients with chronic angina
pectoris in Spain, from the payer’s perspective. METHODS: We use a decision tree
model with a time horizon of one year, under the Spanish health service perspec-
tive. Transition probabilities and utility levels for different angina frequencies were
obtained from published clinical trials. Costs were obtained from Spanish official
DRGs for patients with chronic angina pectoris. We calculate the incremental cost
utility ratio of using ranolazine compared with placebo as an add-on treatment.
Sensitivity analyses include Monte Carlo simulations and ANCOVA models.
RESULTS: The incremental cost utility ratio is 8455 € per QALY per patient in Spain.
Sensitivity analyses show that if the decision makers= willingness to pay is set at
half the usual threshold (15.000 € per QALY), the treatment with ranolazine will be
cost effective at a 95% level of confidence. The incremental cost utility ratio is
particularly sensitive to changes in the level of utility of those non hospitalized
patients with mild or moderate angina frequency. The cost of ranolazine explains
6.44% of the variation in our results. CONCLUSIONS: Ranolazine is a very cost
effective add-on therapy for the symptomatic treatment of chronic angina pectoris
in patients who are inadequately controlled by or intolerant to first-line antianginal
therapies in Spain.
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OBJECTIVES: Cardiovascular disease is a major cause of illness and death. The
polypill seems to offer a promising strategy in the prevention of cardiovascular
diseases. The aim of the present study was to estimate the cost-effectiveness of the
polypill in the primary prevention of cardiovascular diseases in people at a 10 years
risk of cardiovascular death of 5%, 7,5% and 10% or above in the The Netherlands.
METHODS: A computer simulation study was conducted, in which people eligible
for prescription were identified by opportunistic screening. The polypill was of-
fered in different compositions: scenario 1: the polypill as used in the Indian poly-
cap study, with three different types of blood pressure lowering drugs, a lipid
lowering drug, and an antiplatelet agent, scenario 2: as 1) but without aspirin,
scenario 3: as 2) but with a double statin dose (which is the standard in The Neth-
erlands), and scenario 4: separate antihypertensive and/or statin medication. Out-
come measures were cases of acute myocardial infarction and stroke prevented,
QALYs gained, and the costs per QALY gained. RESULTS: All scenarios are cost-
effective with an incremental cost-effectiveness ratio between €8,700-12,000 per
QALY compared with usual care. The most preferable is scenario 3, because for all
risk thresholds most health gain was reached. At a 10-years risk of 7.5% scenario 3
would prevent approximately 3%-5% of all cardiovascular events. CONCLUSIONS:
Depending on the cardiovascular risk, opportunistic screening in combination with
the polypill or separate medication offers a cost-effective strategy. Most health
gain is achieved by the polypill without aspirin and a double statin dose. The major
advantage of a polypill without aspirin is avoiding aspirin’s adverse effects.
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OBJECTIVES: To assess the cost-effectiveness of the anti-arrhythmic agent drone-
darone for the prevention of cardiovascular disease (CVD, comprising myocardial
infarction and stroke) and death among Australian patients with atrial fibrillation
(AF). METHODS: A Markov model was developed with one-year cycles and three
health states: ‘Alive without CVD’, ‘Alive post CVD’ and ‘Dead’. Model subjects’
cardiovascular and mortality risks were derived from a cohort study of 313 AF
patients from the Geelong Hospital, a tertiary hospital in Victoria, Australia. Deci-
sion analysis quantified the health and economic effects of giving all patients
dronedarone versus usual care. Data regarding the efficacy of dronedarone were
derived from the two-year ‘ATHENA’ randomized controlled trial (Hohnlosser, New
Engl J Med, 2009). This showed that compared to placebo, dronedarone 400mg bd
reduced the risk of hospitalized cardiovascular events and death by 24% (hazard
ratio 0.76, 95%CI 0.69-0.84). Relevant costs and utilities were drawn from published
sources. The annual cost of dronedarone was AUD $1668. Follow-up was simulated
for ten years, with application of a 5% annual discount rate to costs and years lived.
RESULTS: In the usual care arm, 26.3% and 12.0% of the cohort were predicted to
suffer myocardial infarctions and strokes, respectively. The equivalent figures in
the dronedarone arm were 21.4% and 9.7%, equating to numbers needed to treat of
20.3 for myocardial infarction and 44.6 for stroke. Compared to usual care, each
dronedarone subject lived an extra 0.44 years and 0.35 QALYs (discounted). Net
costs of dronedarone amounted to AUD $4495 per subject (discounted). Incremen-
tal cost-effectiveness ratios were therefore AUD $10,187 per life year gained and
AUD $12,966 per QALY gained. Sensitivity analyses indicated the results to be
robust. CONCLUSIONS: Dronedarone represents a cost-effective means to prevent
downstream cardiovascular morbidity and mortality among Australian patients
with AF.
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OBJECTIVES: Emerging evidence shows that the prevalence of hypertension is on
the rise in most African countries while control remains poor. There are effective
interventions which could be implemented in hospitals of low resource setting to
improve control of blood pressure amongst hypertensive patients. This study
aimed to evaluate the cost-effectiveness of interventions that could be imple-
mented in Nigerian hospitals in order to ensure better control of high blood pres-
sure in patients with hypertension. METHODS: The study employed decision ana-
lytic modeling. Interventions were obtained from a meta-analysis. The Markov
process model calculated clinical outcomes and costs during a life cycle of 30 years
of 1000 hypertensives stratified by 3 cardiovascular risk groups, under the alterna-
tive intervention scenarios. Quality adjusted life year (QALY) was used to quantify
clinical outcome. The average cost of treatment for the 1000 patient was tracked
over the Markov cycle model of the alternative interventions and results were
presented in Nigerian Naira. Probabilistic cost-effectiveness analysis was per-
formed using Monte Carlo simulation, and results presented as cost-effectiveness
acceptability curves and frontiers. Population expected value of perfect informa-
tion analysis was also conducted. RESULTS: Patient education intervention was
the most cost-effective option across the 3 cardiovascular risk groups except in
high cardiovascular risk scenario where a trade-off has to be made in terms of
commitment of extra fund (approximately N10,000 per QALY). Professional led care
was the second best consistent option across the 3 cardiovascular risk groups
although it will require extra financial investment to the tune of N30,000 per QALY.
CONCLUSIONS: The result of this study shows that patient education programme
followed by professional led care intervention could be a feasible strategy in order
to ensure that patients with high blood pressure are better controlled.
PCV96
COST-UTILITY ANALYSIS OF THE LONG-TERM CARDIOVASCULAR PREVENTION
PROGRAM IN RUSSIAN FEDERATION AS AN ARGUMENT FOR THE WIDESPREAD
INTRODUCTION OF PREVENTIVE TECHNOLOGIES INTO CLINICAL PRACTICE
Kontsevaya A, Kalinina A, Deev A
National reseacrh center for preventive medicine, Moscow, Russia
OBJECTIVES: To evaluate the economic efficiency of 10-years cardiovascular pre-
vention program in primary care of Russian Federation.METHODS: In 1977-1990 in
Moscow a large prevention project was realized. The project was realized in two
primary care areas of Moscow and included men with baseline age 40-59. One
primary care area was intervention area where cardiovascular prevention program
was realized during the 5 years, other area was control. Participants of intervention
(n3488) and control primary care areas (n3168) had the similar age, education
and cardiovascular morbidity. The cardiovascular prevention program included
preventive counseling for participants with CVD risk factors. All cardiovascular
endpoints were registered during 10 years. In this study we calculated the gain of
life years saved (LYS) and quality adjusted life years (QALY) in intervention group
compared with control group (on 1000 participants) during the 5 years on the in-
tervention and during 10 years of total follow up period. Also we calculate the total
cost of the program in the prices of 2008 years. The cost utility analysis was con-
ducted with calculation of cost per gained QALY during 5 years and during 10 year.
RESULTS: The number of gained LYS in the intervention group was 45.7 on 1000
participants in 5 years and 139.4 – in 10 years. The number of QALY was 46.2 and
132.7 on 1000 participants in 5 and 10 years accordingly. The total costs were
174,124$ on 1000 participant in 5 years and 237,928$ in 10 years. Cost per QALY
gained was 3769$ during the 5 years and 1793$ during the 5 years. The gross do-
mestic product per capita in 2008 was 11,806$. CONCLUSIONS: Cardiovascular
prevention program for men aged 40-59 is highly cost-effective and economic ar-
guments can be used for policy-makers.
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